Optimal Ceftazidime/Avibactam Dosing Exposure against KPC-producing Klebsiella pneumoniae. Klebsiella pneumoniae

Objectives: Infections due to carbapenem-resistant Enterobacterales are considered urgent public health threats and often treated with a beta-lactam/beta-lactamase inhibitor combination. However, clinical treatment failure and resistance emergence have been attributed to inadequate dosing. We used a novel framework to provide insights of optimal dosing strategy of ceftazidime/avibactam.Conclusion: An optimal drug exposure to suppress KPC-producing bacteria was identified. The novel framework is informative and may be used to guide optimal dosing of other beta-lactam/beta-lactamase inhibitor combinations. Further in vivo investigations are warranted.